Annual report pursuant to Section 13 and 15(d)

Collaboration and License Agreements - Additional Information (Details1)

v3.19.1
Collaboration and License Agreements - Additional Information (Details1)
Dec. 31, 2018
Aug. 31, 2018
Aug. 31, 2017
Sep. 30, 2014
2014 Celgene Agreement | Celgene | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2014-09-01        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Revenue recognized from payments ratably over period       3 years
2017 Celgene Agreement | Celgene | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2017-08-01        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Revenue recognized from payments ratably over period     3 years  
2018 Merck Agreement | Merck | Collaboration Revenue, Research and Development Services | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2018-07-01        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Revenue recognized from payments ratably over period   3 years    
MDA Agreement | EMD Serono | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2014-06-01        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Revenue recognized from payments ratably over period 5 years